Ivan Tkáč, Lucia Baldaufová
The program DIASAVE included 1 542 patients with type 2 diabetes older than 60 years of age. The aim of the program was to characterize risk profile of type 2 diabetics ambulatory treated and find out the possibility of reaching the target glycohemoglobin levels within the period of 6 months time. Dosis of 30-120 mg of gliclazid MR was added in two-stage titration to current therapy - regime regulations or monotherapy by metformin. Dosis of gliclazid was titrated upwards to get the target levels of glyco hemoglobin (HbA1c) < 6.5 % within 6 months. With the exception of higher age and lower HbA1c levels, the risk profile of diabetics included into the DIASAVE program did not significantly differ in other risk factors from the profile of 1 471 newly diagnosed type 2 diabetics from our previous epidemiological study (1). Therapy with gliclazid MR within 6 months lead to decreasing of HbA1c range 1.4-1.7 % in groups of diabetics older than 60 who had been without pharmacological therapy or treated by monotherapy with metformin. Decreasing of HbA1c resulted in decreasing of 10-year absolute risk of fatal ischemia development in range of 3.1-6.1 %. The highest therapeutical benefit was reported in patients treated by monotherapy with metformin. Therapy with gliclazid MR was an effective part of diabetes therapy and contributed to better glycemic compensation as a risk factor for development of microvascular and macrovascular complications.